Coxiella burnetii is a gram-negative, obligate intracellular bacterial pathogen (a type of bacterium that lives inside the cells of its host) and the causative agent of Q fever. Although it was historically grouped with Rickettsia because of similar cell morphology, genetic and physiological studies show that C. burnetii is distinct and belongs to the class Gammaproteobacteria, and it is currently the only confirmed species within the genus Coxiella. The bacterium is a small coccobacillus with a unique ability to survive in extremely harsh environmental conditions. It forms a highly resistant small-cell variant (SCV) as part of a two-stage developmental cycle, which alternates with a metabolically active large-cell variant (LCV) that replicates inside host cells. These adaptations allow C. burnetii to survive common disinfectants and to persist within host cells, including in harsh environments such as the acidic phagolysosome.

The RML team initially proposed the name Rickettsia diaporica, derived from the Greek word meaning "passing through", in reference to the organism's ability to pass through bacterial filters. Around the same time, Edward Derrick suggested the name Rickettsia burnetii to recognize Macfarlane Burnet's contribution in identifying the agent as a rickettsial organism.

The first effective Q fever vaccine was developed in the 1960s–1970s through a collaboration between American microbiologist Richard Ormsbee and Australian infectious diseases physician Barrie Marmion.

Coxiella was historically difficult to study because it could not be grown outside a host. In 2009, researchers established an axenic (host-free) culture system that allowed C. burnetii to be grown in cell-free media, enabling more detailed molecular biology studies.

Pathogenesis

thumb|left|200px|Immunohistochemical detection of C. burnetii in resected cardiac valve of a 60-year-old man with Q fever endocarditis, Cayenne, French Guiana, monoclonal antibody against C. burnetii and hematoxylin were used for staining: Original magnification ×50

Virulence and infectious dose

Of the many C. burnetii isolates, several strains are now used most often in research because they are well-characterized and widely available. The Nine Mile phase I strain remains the standard reference strain for genetic and virulence studies. In addition, the Guiana strain has also become an important focus of recent research because it is more virulent in animal models than the Nine Mile strain. In recent years, additional strains have been examined, broadening the diversity of isolates used in research.

The median infectious dose (ID<sub>50</sub>), the number of organisms required to infect 50% of exposed individuals, is estimated to be as low as a single bacterium when inhaled. This represents an extremely low infectious dose (approximately 1 to 10 organisms), making Coxiella burnetii one of the most infectious bacterial pathogens known. The disease occurs in two stages: an acute phase characterized by fever, chills, and respiratory symptoms, and a chronic phase that develops more slowly and may involve endocarditis or hepatitis. Upon inhalation, the bacterium targets alveolar macrophages and enters through actin-dependent phagocytosis.

After entry into a host cell, SCVs are taken up into a phagosome that matures through the endocytic pathway. In the first few hours after infection, the compartment merges with endosomes, autophagosomes, and lysosomes containing acid phosphatase picking up acidic hydrolases and lysosomal proteins along the way. The acidic environment inside the vacuole triggers the SCVs to transform into the metabolically active LCVs, which are then able to replicate within the C. burnetii-containing vacuole (CCV).

At this stage, C. burnetii becomes metabolically active and synthesizes a type IV secretion system (T4SS) which translocates effector proteins into the host cytoplasm to manipulate host cell functions.

Type IVB secretion system

The bacteria use a type IVB secretion system known as Icm/Dot (intracellular multiplication / defect in organelle trafficking genes) to inject over 100 effector proteins into the host. These effectors increase the bacterium's ability to survive and replicate within host cells by modulating multiple host pathways, including blocking apoptosis, inhibiting immune responses, and altering vesicle trafficking. In Legionella pneumophila, a related Gammaproteobacterium that uses the same secretion system, these effectors enhance survival by preventing fusion of the bacteria-containing vacuole with degradative endosomes.

Treatment and prevention

Acute Q fever is typically treated with doxycycline, which shortens illness duration and reduces the risk of progression to chronic disease. Other antibiotics, including macrolides, co-trimoxazole, quinolones, and beta-lactams, have been used but show less consistent effectiveness. Serologic tests may not become positive until 1–2 weeks after exposure, so the CDC recommends initiating doxycycline based on clinical suspicion rather than waiting for laboratory confirmation.

In livestock, parts of the European Union authorize vaccination using Coxevac (a phase I killed C. burnetii vaccine) on goats to reduce the risk of abortion and C. burnetii transfer through vaginal fluids, feces, and milk. It is also used for the treatment of C. burnetii infection in cattle. The effects of the vaccine are most pronounced in goats when vaccinated before their first pregnancy.

Chronic Q fever, particularly endocarditis, requires prolonged combination therapy. The most effective regimen is doxycycline with hydroxychloroquine for at least 18 months, and patients undergoing treatment require long-term serologic monitoring to ensure clearance of infection and detect relapse.

Prevalence and host

Coxiella burnetii is a globally distributed microbe (excluding New Zealand and Antarctica) found commonly in domestic reservoirs such as sheep, goats, and cattle.

thumb|353x353px|Map of global distribution patterns of reported Q fever outbreaks in 2024

Q fever is present in German human populations with 27-100 cases reported annually. It is estimated to affect 50 per every 100,000 inhabitants annually in France. The UK has faced 904 cases between 2000 and 2015, as well as major outbreaks in 2002 and 2007. Italy has experienced two different outbreaks of human infection in Como prison and Vicenza respectively. Spain has a high prevalence of C. burnetii infection in human populations in Basque and Navarre. The annual reported cases of human C. burnetii infection in the US went up from 19 cases in 2000 to around 160-180 cases per year, with 178 acute cases in 2019. In the US, cases of human infection were mainly found in the West or the Great Plains regions of the country. Canada has a low human incidence of infection. In Quebec, it was reported that there were 0.4 cases per 100,000 inhabitants in 2017. In Alberta, only 39 cases were reported. Coxiella burnetii has been observed with a greater prevalence in populations in close proximity to animals as well as homeless populations in Brazil. In Algeria, residing in rural areas is a risk factor for contracting Coxiella burnetii infections compared to inhabitants of urban areas. Isiolo County, Kenya has been found to have a 44.7% seroprevalence of Coxiella burnetii in humans. In Kwara State, Nigeria, C. burnetii was found with a 18.8% prevalence in milk and cheese, contributing to further transmission of Q fever through consumption of milk products.

Coxiella burnetii and bacteria similar to it were found in tick species that populate wildlife in South Korea. The microbe has also been found in ticks that were collected from Churra Galega Mirandesa sheep in Portugal. Isiolo County, Kenya has been found to have a 47.9% seroprevalence of C. burnetii in livestock. There are many unique aspects of C. burnetii that made it an attractive target of weaponization research. Most notably, C. burnetii maintains the lowest known pathogenic infectious dose, with some studies reporting that as low as one individual organism can incite infection in a human target.

Common C. burnetii infections manifest as low grade flu-like symptoms, headache, malaise, and persistent myalgia. While the mortality rate for C. burnetii is only around 0.5-1.5%, the bacteria can persist in the body for years and develop into chronic Q fever with further intense complications. Around 20% of those infected with C. burnetii will experience chronic fatigue and symptoms that can last years or indefinitely after initial exposure.

The United States, Iraq, and the Soviet Union were among the countries heading research into the potential use of C. burnetii as a deliberately dispersed infectious agent in the mid-1900s. In the United States, C. burnetii was field tested as an aerosolized infection in both animal and rodent trials at the Dugway Proving Ground in Utah, USA. Field testing allowed researchers the opportunity to observe and draw conclusions regarding the bacteria's infectious dose, symptoms of disease, and progress into potential treatments. Testing of both rodent and human subjects within the same environment allowed for confirmation that C. burnetii can be transmitted from animals to humans. which contain about 2.1 million base pairs of DNA each and encode around 2,100 open reading frames (ORFs), which are stretches of DNA that can be read to produce proteins; 746 (or about 35%) of these genes have no known function.

Recent advances in sequencing techniques, particularly selective whole genome amplification (SWGA), allowed for the recovery of even more C. burnetii genomes. These samples were found in clinical and environmental studies. In one study, researchers applied SWGA to environmental samples such as unpasteurized milk and goat vaginal swabs. The technique helped increase the amount of C. burnetii DNA found in the samples by up to 147 times more than before. This improvement dramatically increased bacterial reads and genome coverage from less than 1% of sequence reads to as high as 74%, providing enough genetic information to compare different strains and understand how they are related. The ability to sequence C. burnetii even when it is present in very small amounts helps expand what we know about its genetic diversity and supports better tracking of how the bacteria spread and evolve.

In bacteria, molecules called small regulatory RNAs are activated during stress and virulence conditions. In Coxiella burnetii, several of these small RNAs (named CbSRs 1, 11, 12, and 14) are encoded within intergenic regions (IGR), or the DNA between genes. CbSRs 2, 3, 4 and 9 are located complementary to identified ORFs. The CbSRs are up-regulated during intracellular growth in host cells.

All C. burnetii strains contain extra genetic material - either one of four large plasmids (QpH1, QpDG, QpRS, or QpDV) or a piece of DNA in the chromosome that originated from the QpRS plasmid. The QpH1 plasmid plays a key role in helping the bacteria survive inside host cells such as mouse macrophages and Vero cells, although it is not needed for growth in artificial (axenic) culture. QpH1 also contains a toxin-antitoxin system, which may help the plasmid remain stable in the bacteria. Among all of these plasmids, eight conserved genes produce proteins that the bacteria inject into the host cells via the secretion system. Due to its zoonotic transmission pathways and exceptional environmental persistence, C. burnetii is regarded as a priority pathogen within the One Health approach. Its ability to resist environmental stressors and infect a broad range of hosts allows the circulation of C. burnetii between diverse hosts and environments. Rural populations are often in closer contact with C. burnetii than urban or suburban communities due to proximity to livestock. A range of antibiotics and combination therapies have been found to be effective at clearing individual infections after detection and onset of symptoms. The Q-Vax vaccine can provide effective prevention of an initial infection, although this vaccine has not been widely implemented due to high incidence of a post-vaccination hypersensitivity reaction. Ongoing research is focussed on remodelling this vaccine to ensure that side effects are minimized and widespread deployment is successful. The global distribution of C. burnetii can be attributed to its uniquely resilient small cell variant that is able to be dispersed miles by wind and persist in its environment for years. Diagnosis of a C. burnetii infection remains difficult, as its acute manifestation can resemble that of many other non-specific and self-limiting infectious diseases. Control of outbreaks is further complicated by the pathogens environmental resilience, capacity for aerosol transmission, and widespread distribution. Lack of a widely approved vaccine and the difficulty of detecting C. burnetii make it an ongoing subject of public health and infectious disease research.

References

  • Coxiella burnetii genomes and related information at PATRIC, a Bioinformatics Resource Center funded by NIAID